Pharmacokinetics of etoricoxib in patients with hepatic impairment

Journal of Clinical Pharmacology

Volumn 43, Issue 10, 2003, Pages 1136-1148

  Agrawal, Nancy G B ^a   Rose, Mark J ^a   Matthews, Catherine Z ^a   Woolf, Eric J ^a   Porras, Arturo G ^a   Geer, Leslie A ^a   Larson, Patrick J ^a   Cote, Josee ^a   Dilzer, Stacy C ^b   Lasseter, Kenneth C ^b   Alam, Imtiaz ^c   Petty, Kevin J ^a   Gottesdiener, Keith M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

^c Center for Clinical Research   (United States)

Author keywords

Bioavailability; COX 2; Cyclooxygenase; Etoricoxib; Hepatic impairment; Pharmacokinetics

Indexed keywords

CARBON 13; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; ETORICOXIB C 13; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; ISOTOPE LABELING; LIVER DISEASE; MALE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADMINISTRATION, ORAL; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PYRIDINES; SULFONES;

EID: 10744233921     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003257219     Document Type: Article

References (17)

1. Vane JR, Botting RM: The history of anti-inflammatory drugs and their mechanism of action, in: Bazan N, Botting J, Valle J (eds.), New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules. London: Kluwer Academic and William Harvey Press, 1996;1-12.
2. Smith WL, DeWitt DL: Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995;15:179-194.
3. Donnelly MT, Hawkey CJ: COX-II inhibitors-a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997;11:227-236.
4. Jouzeau J-Y, Terlain B, Abid A, Nedelec E, Netter P: Cyclooxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-582.
5. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-11697.
6. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
7. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-1933.
8. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558-566.
9. Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, et al: Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos; 2003; 31:224-232.
10. Child CG, Turcotte JG: Surgery and portal hypertension, in: Child CG (ed.), The Liver and Portal Hypertension. Philadelphia: W. B. Saunders, 1964;50-52.
11. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
12. Matthews CZ, Woolf EJ, Lin L, Fang W, Hsieh J, Ha S, et al: High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection. J Chromatogr B 2001;751:237-246.
13. Rose MJ, Agrawal N, Woolf EJ, Matuszewski BK: Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS. J Pharm Sci 2002;91:405-416.
14. Yeh KC, Remphrey K: A simplex optimization program. Pharm Res 1990;7:S244.
15. Agrawal NGB, Porras AG, Matthews CZ, Woolf EJ, Miller JL, Mukhopadhyay S, et al: Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001;41:1106-1110.
16. Agrawal NGB, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ, et al: Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003;43(3):268-276.
17. Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, et al: Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology 2002;41:1052-1061.